Clinical Trial

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with metastatic or unresectable solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-03; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-07-07
Trial Details
NCT Number NCT06719362
Lead Sponsor Providence Health & Services
Conditions Advanced Solid Tumors
Enrollment 110 participants
Start Date 2025-06-17
Primary Completion 2028-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-23